Gate Neurosciences and the University of Pittsburgh have initiated a Phase II trial to explore combining the antidepressant drug apimostinel with the university's digital therapy ASAT. The study aims to extend the drug's efficacy for treating depression by leveraging neuroplasticity.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing